Tirofiban potentiates agonist-induced platelet activation and degranulation, despite effectively inhibiting aggregation

References

• Michelson AD. 2012. Platelets. Academic Press, London.
   Google Scholar
• Yazdani A, Yazdani A, Li X, Douglas KAA, Mantzoros CS, Karniadakis GE. 2018. Quantifying platelet margination in diabetic blood flow. Biophys J. 1157:1371–1382. doi:10.1016/j.bpj.2018.08.031.
   PubMed Web of Science ®Google Scholar
• Li JL, Zarbock A, Hidalgo A. 2017. Platelets as autonomous drones for hemostatic and immune surveillance. J Exp Med. 2148:2193–2204. doi:10.1084/jem.20170879.
   PubMed Web of Science ®Google Scholar
• McDonald B, Dunbar M. 2019. Platelets and intravascular immunity: guardians of the vascular space during bloodstream infections and sepsis. Front Immunol. 10:1–13. doi:10.3389/fimmu.2019.02400.
   PubMed Web of Science ®Google Scholar
• Contursi A, Sacco A, Grande R, Dovizio M, Patrignani P. 2017. Platelets as crucial partners for tumor metastasis: from mechanistic aspects to pharmacological targeting. Cell Mol Life Sci. 7419:3491–3507. doi:10.1007/s00018-017-2536-7.
   PubMed Web of Science ®Google Scholar
• Haemmerle M, Stone RL, Menter DG, Afshar-Kharghan V, Sood AK. 2018. The platelet lifeline to cancer: challenges and opportunities. Cancer Cell. 336:965–983. doi:10.1016/j.ccell.2018.03.002.
   PubMed Web of Science ®Google Scholar
• Rivera J, Lozano ML, Navarro-Núñez L, Vicente García V. 2009. Platelet receptors and signaling in the dynamics of thrombus formation. Haematologica. 945:700–711. doi:10.3324/haematol.2008.003178.
   PubMed Web of Science ®Google Scholar
• Tomaiuolo M, Brass LF, Stalker TJ. 2017. Regulation of platelet activation and coagulation and its role in vascular injury and arterial thrombosis. Interv Cardiol Clin. 61:1–12. doi:10.1016/j.iccl.2016.08.001.
   PubMedGoogle Scholar
• Farndale RW, Sixma JJ, Barnes MJ, De Groot PG. 2004. The role of collagen in thrombosis and hemostasis. J Thromb Haemost. 24:561–573. doi:10.1111/j.1538-7836.2004.00665.x.
   PubMed Web of Science ®Google Scholar
• Offermanns S. 2006. Activation of platelet function through G protein-coupled receptors. Circ Res. 9912:1293–1304. doi:10.1161/01.RES.0000251742.71301.16.
   PubMed Web of Science ®Google Scholar
• Yun S-H, Sim E-H, Goh R-Y, Park J-I, Han J-Y. 2016. Platelet activation: the mechanisms and potential biomarkers. Biomed Res Int. 2016:9060143. doi:10.1155/2016/9060143.
   PubMed Web of Science ®Google Scholar
• Li Z, Delaney MK, O’Brien KA, Du X. 2010. Signaling during platelet adhesion and activation. Arterioscler Thromb Vasc Biol. 312:2341–2349. doi:10.1161/ATVBAHA.110.207522.
   Google Scholar
• Marguerie GA, Plow EF, Edgington TS. 1979. Human platelets possess an inducible and saturable receptor specific for fibrinogen. J Biol Chem. 25412:5357–5363. doi:10.1016/S0021-9258(18)50603-7.
   PubMed Web of Science ®Google Scholar
• Huang J, Kantarjian H, Atallah R, Gonzalez GN, Issa GC, Rios MB, Garcia-Manero G, Borthakur G, Ravandi F, Jain N. 2019. Platelet integrin αiIbβ3: signal transduction, regulation, and its therapeutic targeting. J Hematol Oncol. 121:1–22. doi:10.1186/s13045-019-0709-6.
   PubMed Web of Science ®Google Scholar
• Chapin JC, Hajjar KA. 2015. Fibrinolysis and the control of blood coagulation NIH public access. Blood Rev. 291:17–24. doi:10.1016/j.blre.2014.09.003.
   PubMed Web of Science ®Google Scholar
• Wendelboe AM, Raskob GE. 2016. Global burden of thrombosis: epidemiologic aspects. Circ Res. 1189:1340–1347. doi:10.1161/CIRCRESAHA.115.306841.
   PubMed Web of Science ®Google Scholar
• Fuentes A, Pineda M, Venkata K. 2018. Comprehension of top 200 prescribed drugs in the US as a resource for pharmacy teaching, training and practice. Pharmacy. 62:43. doi:10.3390/pharmacy6020043.
   Web of Science ®Google Scholar
• Schneider DJ, Herrmann HC, Lakkis N, Aguirre F, Wan Y, Aggarwal A, Kabbani SS, DiBattiste PM. 2002. Enhanced early inhibition of platelet aggregation with an increased bolus of tirofiban. Am J Cardiol. 912:1421–1423. doi:10.1016/S0002-9149(02)02892-8.
   Google Scholar
• Kereiakes DJ, Kleiman NS, Ambrose J, Cohen M, Rodriguez S, Palabrica T, Herrmann HC, Sutton JM, Weaver WD, McKee DB. 1996. Randomized, double-blind, placebo-controlled dose-ranging study of tirofiban (MK-383) platelet IIb/IIIa blockade in high risk patients undergoing coronary angioplasty. J Am Coll Cardiol. 273:536–542. doi:10.1016/0735-1097(95)00500-5.
   PubMed Web of Science ®Google Scholar
• Juwana YB, Suryapranata H, Ottervanger JP, van ‘t Hof AW. 2010. Tirofiban for myocardial infarction. Expert Opin Pharmacother. 115:861–866. doi:10.1517/14656561003690005.
   PubMed Web of Science ®Google Scholar
• Guo Y, Zhao Z, Li S, Chen L. 2021. Clinical efficacy and safety of tirofiban combined with conventional dual antiplatelet therapy in ACS patients undergoing PCI. Sci Rep. 11(1):17144. doi: 10.1038/s41598-021-96606-y.
   Web of Science ®Google Scholar
• Kral JB, Schrottmaier WC, Salzmann M, Assinger A. 2016. Platelet interaction with innate immune cells. Transfus Med Hemotherapy. 432:78–88. doi:10.1159/000444807.
   PubMed Web of Science ®Google Scholar
• McKinnon K. 2019. Flow cytometry: an overview. Cell Vis. 120:1–11. doi:10.1002/cpim.40.
   Google Scholar
• Macwan AS, Boknäs N, Ntzouni MP, Ramström S, Gibbins JM, Faxälv L, Lindahl TL. 2019. Gradient-dependent inhibition of stimulatory signaling from platelet G protein-coupled receptors. Haematologica. 1047:1482–1492. do i:10.3324/haematol.2018.205815.
   PubMed Web of Science ®Google Scholar
• Mitrugno A, Williams D, Kerrigan SW, Moran N. 2014. A novel and essential role for FcγRIIa in cancer cell-induced platelet activation. Blood. 1232:249–260. doi:10.1182/blood-2013-03-492447.
   PubMed Web of Science ®Google Scholar
• Sun D, Popescu NI, Raisley B, Keshari RS, Dale GL, Lupu F, Coggeshall KM. 2013. Bacillus anthracis peptidoglycan activates human platelets through FcγRII and complement. Blood. 1224:571–579. doi:10.1182/blood-2013-02-486613.
   PubMed Web of Science ®Google Scholar
• Bassler N, Loeffler C, Mangin P, Yuan Y, Schwarz M, Hagemeyer CE, Eisenhardt SU, Ahrens I, Bode C, Jackson SP. 2007. A mechanistic model for paradoxical platelet activation by ligand-mimetic α IIb β 3 (GPIIb/IIIa) antagonists. Arterioscler Thromb Vasc Biol. 273:9–15. doi:10.1161/01.ATV.0000255307.65939.59.
   PubMed Web of Science ®Google Scholar
• Niedergang F, Alcover A, Knight CG, Farndale RW, Barnes MJ, Francischetti IMB, Bon C, Leduc M. 2000. Convulxin binding to platelet receptor GPVI: competition with collagen related peptides. Biochem Biophys Res Commun. 2731:246–250. doi:10.1006/bbrc.2000.2940.
   PubMed Web of Science ®Google Scholar
• Chacko GW, Duchemin AM, Coggeshall KM, Osborne JM, Brandt JT, Anderson CL. 1994. Clustering of the platelet Fcγ receptor induces noncovalent association with the tyrosine kinase p72 (syk). J Biol Chem. 26951:32435–32440. doi:10.1016/S0021-9258(18)31653-3.
   PubMed Web of Science ®Google Scholar
• Lee H, Kim G, Lim C, Lee BK, Shin S. 2016. A simple method for activating the platelets used in microfluidic platelet aggregation tests: stirring-induced platelet activation. Biomicrofluidics. 16:064118. doi:10.1063/1.4972077.
   Google Scholar
• Hsu-Lin S-C, Berman CL, Furie BC, August D, Furie B. 1984. A platelet membrane protein expressed during platelet activation and secretion. J Biol Chem. 25914:912109126. doi:10.1016/S0021-9258(17)47274-7.
   Web of Science ®Google Scholar
• Heijnen H, van der Sluijs P. 2015. Platelet secretory behaviour: as diverse as the granules … or not? J Thromb Haemost. 1312:2141–2151. doi:10.1111/jth.13147.
   PubMed Web of Science ®Google Scholar
• Topol EJ, Byzova TV, Plow EF. 1999. New drug classes platelet GPIIb-IIIa blockers. Lancet. 353(9148):227–231. doi:10.1016/S0140-6736(98)11086-3.
   PubMed Web of Science ®Google Scholar
• Straub A, Schiebold D, Wendel HP, Azevedo R, Dietz K, Ziemer G. 2008. Platelet anaesthesia during extracorporeal circulation: differential effects of GP IIb/IIIa blockers on platelet activation marker P-selectin expression at hypothermia. Thromb Res. 1223:383–389. doi:10.1016/j.thromres.2008.01.001.
   PubMed Web of Science ®Google Scholar
• Matzdorff AC, Kühnel G, Kemkes-Matthes B, Voss R. 2001. Comparison of GP IIB/IIIA inhibitors and their activity as measured by aggregometry, flow cytometry, single platelet counting, and the rapid platelet function analyzer. J Thromb Thrombolysis. 122:129–139. doi:10.1023/A:1012967320220.
   PubMed Web of Science ®Google Scholar
• Maynard DM, Heijnen HFG, Horne MK, White JG, Gahl WA. 2007. Proteomic analysis of platelet α-granules using mass spectrometry. J Thromb Haemost. 59:1945–1955. doi:10.1111/j.1538-7836.2007.02690.x.
   PubMed Web of Science ®Google Scholar
• Pagel O, Walter E, Jurk K, Zahedi RP. 2017. Taking the stock of granule cargo: platelet releasate proteomics. Platelets. 282:119–128. doi:10.1080/09537104.2016.1254762.
   PubMed Web of Science ®Google Scholar
• Chen Y, Yuan Y, Li W. 2018. Sorting machineries: how platelet-dense granules differ from α-granules. Biosci Rep. 385. doi:10.1042/BSR20180458.
   Google Scholar
• Deppermann C. 2018. Platelets and vascular integrity. Platelets. 296:549–555. doi:10.1080/09537104.2018.1428739.
   PubMed Web of Science ®Google Scholar
• Golebiewska EM, Poole AW. 2015. Platelet secretion: from haemostasis to wound healing and beyond. Blood Rev. 293:153–162. doi:10.1016/j.blre.2014.10.003.
   PubMed Web of Science ®Google Scholar
• Blair P, Flaumenhaft R. 2009. Platelet Alpha–granules: basic biology and clinical correlates price. Blood Rev. 234:177–189. doi:10.1016/j.blre.2009.04.001.
   PubMed Web of Science ®Google Scholar
• Italiano JE, Battinelli EM. 2009. Selective sorting of alpha-granule proteins. J Thromb Haemost. 7:173–176. doi:10.1111/j.1538-7836.2009.03387.x.
   PubMed Web of Science ®Google Scholar
• White JG. 2013. Platelet structure. In: Michelson AD, editor. Platelets. Academic Press; 117–144.
   Google Scholar
• Engelmann B, Massberg S. 2013. Thrombosis as an intravascular effector of innate immunity. Nat Rev Immunol. 131:34–45. doi:10.1038/nri3345.
   PubMed Web of Science ®Google Scholar
• Verschoor A, Langer HF. 2013. Crosstalk between platelets and the complement system in immune protection and disease. Thromb Haemost. 1111:910–919. doi:10.1160/TH13-02-0102.
   Google Scholar
• Von HP, Koenen RR, Sack M, Mause SF, Adriaens W, Proudfoot AEI, Hackeng TM, Weber C. 2005. Heterophilic interactions of platelet factor 4 and RANTES promote monocyte arrest on endothelium. Blood. 1053:924–930. doi:10.1182/blood-2004-06-2475
   PubMed Web of Science ®Google Scholar
• Kramp BK, Megens RTA, Sarabi A, Winkler S, Projahn D, Weber C, Koenen RR, von Hundelshausen P. 2013. Exchange of extracellular domains of CCR1 and CCR5 reveals confined functions in CCL5-mediated cell recruitment. Thromb Haemost. 1110:795–806. doi:10.1160/TH13-05-0420.
   Google Scholar
• Zuchtriegel G, Uhl B, Puhr-Westerheide D, Pörnbacher M, Lauber K, Krombach F, Reichel CA. 2016. Platelets guide leukocytes to their sites of extravasation. PLoS Biol. 145:1–28. doi:10.1371/journal.pbio.1002459.
   Web of Science ®Google Scholar
• Langer HF, Daub K, Braun G, Schönberger T, May AE, Schaller M, Stein GM, Stellos K, Bueltmann A, Siegel-Axel D, et al. 2007. Platelets recruit human dendritic cells via Mac-1/JAM-C interaction and modulate dendritic cell function in vitro. Arterioscler Thromb Vasc Biol. 276:1463–1470. doi:10.1161/ATVBAHA.107.141515.
   PubMed Web of Science ®Google Scholar
• Etulain J, Martinod K, Wong SL, Cifuni SM, Schattner M, Wagner DD. 2015. P-selectin promotes neutrophil extracellular trap formation in mice. Blood. 1262:242–246. doi:10.1182/blood-2015-01-624023.
   PubMed Web of Science ®Google Scholar
• Serebruany V, Malinin A, Pokov A, Arora U, Atar D, Angiolillo D. 2007. Effects of escalating doses of tirofiban on platelet aggregation and major receptor expression in diabetic patients: hitting the TARGET in the TENACITY trial? Thromb Res. 1192:175–181. doi:10.1016/j.thromres.2006.02.004.
   PubMed Web of Science ®Google Scholar
• Peerlinck K, De Lepeleire I, Goldberg M, Farrell D, Barrett J, Hand E, Panebianco D, Deckmyn H, Vermylen J, Arnout J. 1993. MK-383 (L-700,462), a selective nonpeptide platelet glycoprotein IIb/IIIa antagonist, is active in man. Circulation. 884:1512–1517. doi:10.1161/01.CIR.88.4.1512.
   PubMed Web of Science ®Google Scholar
• Dursunoglu D, Taşköylü Ö, Gür S, Sari I. 2013. Tirofiban-induced acute profound thrombocytopenia after primary angioplasty. Asian Cardiovasc Thorac Ann. 211:74–76. doi:10.1177/0218492312445142.
   PubMedGoogle Scholar
• Li X, Sorokin MI, Emelianova AA, Borisov NM, Kuzmin DV, Borger P, Garazha AV, Buzdin AA. 2019. Platelet function and risk of bleeding in patients with acute coronary syndrome following tirofiban infusion. Front Pharmacol. 10:1–8. doi:10.3389/fphar.2019.01158.
   PubMed Web of Science ®Google Scholar